Schoenfeld JD et al., 2017-04-10: Mechanistic Cancer Cell paper from the University of Iowa group arguing that ascorbate's cancer-selective toxicity runs through labile iron and hydrogen peroxide, and summarising preclinical plus early clinical experience in glioblastoma and lung cancer.
preclinical studies and clinical trials demonstrate the feasibility, selective toxicity, tolerability, and potential efficacy of pharmacological ascorbate in GBM and NSCLC therapy.
Abstract (Cancer Cell 31(4):487-500)
Schoenfeld JD et al., 2017-04-10: Mechanistic Cancer Cell paper from the University of Iowa group arguing that ascorbate's cancer-selective toxicity runs through labile iron and hydrogen peroxide, and summarising preclinical plus early clinical experience in glioblastoma and lung cancer. PMID 28366679; an erratum exists (PMID 28810149, Cancer Cell 32(2):268) – cite the original, note the correction. Funder/COI not captured from the paywalled full text; one author (Riley DP) is affiliated with Galera Therapeutics, a maker of manganese porphyrin dismutase mimics, which is a material tie to a competing product class. Comparator: in vitro cell lines and mouse models plus phase I infusion data; no randomised clinical endpoint. PMCID PMC5497844.
